Follicular Subtype of Papillary Thyroid Carcinoma: Understanding Your Pathology Report

Section Editor: Jason Wasserman MD PhD FRCPC
May 29, 2026

Follicular subtype of papillary thyroid carcinoma is a type of thyroid cancer. It is one of several subtypes of papillary thyroid carcinoma, the most common thyroid cancer overall. Under the microscope, this tumor combines two features: the cells are arranged in small round structures called follicles (the same growth pattern seen in normal thyroid tissue and in follicular thyroid carcinoma), and the cells have specific changes in their nuclei that are characteristic of papillary thyroid carcinoma. The combination of these two features is what defines the diagnosis.

The current World Health Organization (WHO) classification, published in 2022, uses the term follicular subtype. The older term, follicular variant, means the same thing and still appears in many pathology reports during the transition between the two names. The slightly different term, follicular pattern papillary thyroid carcinoma, may also appear. All three terms describe the same tumor.

This article will help you understand the findings in your pathology report, what each term means, and why those findings matter for your care.

What causes the follicular subtype of papillary thyroid carcinoma?

The exact cause is not fully understood. Most cases develop sporadically, meaning they appear without a known trigger and are not caused by anything the person did or was exposed to. The most consistently identified risk factor is exposure to ionizing radiation, particularly during childhood. Examples include radiation therapy to the head and neck given for other cancers in childhood, and large-scale radiation exposure events such as the Chernobyl accident. Most patients with this tumor have no history of radiation exposure.

At the genetic level, the follicular subtype of papillary thyroid carcinoma is most often associated with changes in the RAS family of genes (HRAS, KRAS, NRAS). This molecular pattern differs from that of classic papillary thyroid carcinoma, which is more often associated with changes in the BRAF gene. These differences are discussed further in the biomarker section below.

Most follicular subtype tumors are not inherited. A small minority occur in families with inherited conditions that increase the risk of thyroid cancer, such as familial adenomatous polyposis (FAP), Cowden syndrome (PTEN hamartoma tumor syndrome), Carney complex, Werner syndrome, or DICER1 syndrome. Genetic counseling may be considered when there is a family history of thyroid or related cancers, when the patient is young, or when multiple thyroid tumors are present.

What are the symptoms?

Most patients with the follicular subtype of papillary thyroid carcinoma do not have symptoms. The tumor is often discovered when a thyroid nodule is found on physical examination or by chance on an imaging test performed for another reason. When symptoms do occur, they are similar to those of other thyroid cancers and can include:

A lump or swelling in the front of the neck.
Difficulty swallowing.
Hoarseness or a change in voice.
A persistent cough that is not related to a cold or other infection.
Difficulty breathing, when the tumor is large enough to press on the airway.
Rarely, swelling in the side of the neck from involvement of nearby lymph nodes.

Thyroid hormone levels are usually normal because the tumor cells, although abnormal, generally do not produce enough hormone to cause symptoms.

How is the diagnosis made?

The workup usually begins when a thyroid nodule is found on physical examination or on imaging. A neck ultrasound is then used to evaluate the size, shape, and internal features of the nodule. Some ultrasound features raise the suspicion of cancer, but ultrasound alone cannot determine the subtype.

The next step is most often a fine-needle aspiration (FNA), in which a thin needle is used to remove cells from the nodule for microscopic examination. FNA can identify many cases of classic papillary thyroid carcinoma, but it has important limitations for the follicular subtype. The key features that distinguish the follicular subtype of papillary thyroid carcinoma from related non-cancerous conditions, such as follicular adenoma and NIFTP, are capsular invasion (tumor cells breaking through the capsule surrounding the tumor) and vascular invasion (tumor cells within blood vessels). Neither of these features can be reliably assessed on the small samples obtained by FNA. For this reason, FNA results in this setting are often reported as suspicious for follicular neoplasm, and surgery is needed to make the final diagnosis.

The diagnosis is made after the tumor is surgically removed and examined under the microscope by a pathologist. The surgery is most often a lobectomy (removal of one lobe of the thyroid) or a total thyroidectomy (removal of the entire thyroid gland). The pathologist evaluates the tumor for the nuclear features of papillary thyroid carcinoma, the follicular growth pattern, and the presence or absence of capsular and vascular invasion. The combination of these findings establishes the diagnosis and determines the subtype.

Immunohistochemistry, which uses antibodies to detect specific proteins in tissue, is not usually required to make the diagnosis but may be used in difficult cases or to evaluate the boundary of the tumor and look for early invasion.

Subtypes within the follicular subtype

The WHO 2022 classification divides the follicular subtype of papillary thyroid carcinoma into two main groups based on how the tumor grows in the thyroid gland. The two groups behave somewhat differently and may be treated differently.

Invasive encapsulated follicular subtype — The tumor is surrounded by a fibrous capsule. The diagnosis of carcinoma in this group depends on the presence of capsular invasion (tumor cells crossing the capsule), vascular invasion (tumor cells within blood vessels), or both. The behavior of these tumors is closer to that of follicular thyroid carcinoma than to classic papillary thyroid carcinoma: spread, when it occurs, is more often through the bloodstream to distant sites such as the lungs or bones than through lymphatic channels to lymph nodes. At the genetic level, RAS mutations are common in this group.
Infiltrative follicular subtype — The tumor does not have a clear capsule. Instead, the tumor cells grow into the surrounding thyroid tissue in an infiltrative pattern. The behavior of these tumors is more like that of classic papillary thyroid carcinoma: spread, when it occurs, is more often to nearby lymph nodes. At the genetic level, BRAF mutations are more common in this group.

Some pathology reports, particularly older ones, may use additional descriptive terms such as minimally invasive, widely invasive, or angioinvasive to describe the extent and pattern of invasion. These older descriptions remain useful but are no longer the primary basis for classification in the WHO 2022 system.

NIFTP: a related non-cancerous entity

Until 2016, encapsulated tumors with the nuclear features of papillary thyroid carcinoma but with no capsular or vascular invasion were called non-invasive encapsulated follicular variant of papillary thyroid carcinoma and were considered a form of cancer. Long-term follow-up studies have shown that these tumors behave in a benign manner. They have since been reclassified as non-invasive follicular thyroid neoplasm with papillary-like nuclear features, or NIFTP, and are no longer considered cancer.

The difference between NIFTP and the invasive encapsulated follicular subtype of papillary thyroid carcinoma is invasion. Both have a capsule, and both show the nuclear features of papillary thyroid carcinoma. NIFTP shows no capsular or vascular invasion, while the invasive encapsulated follicular subtype shows one or both. This distinction can only be made after the entire tumor is removed and examined under the microscope.

Tumor size and extrathyroidal extension

After the tumor is removed, the pathologist measures it in three dimensions and records the largest dimension on the report. Tumor size is one of the most important factors in staging the cancer.

The pathologist also looks for extrathyroidal extension, meaning the tumor has grown beyond the thyroid gland into the surrounding tissues. Two patterns are described:

Microscopic extrathyroidal extension — Tumor cells have grown a small distance into the soft tissue around the thyroid, but are only visible under the microscope. This finding has a small effect on prognosis.
Macroscopic (gross) extrathyroidal extension — The tumor visibly invades the structures around the thyroid (such as the neck muscles, the airway, the esophagus, or major blood vessels) during surgery or on imaging. This finding raises the pathologic tumor stage and is associated with a higher risk of recurrence.

Vascular invasion

Vascular invasion, also called angioinvasion, refers to tumor cells present within a blood vessel. In the follicular subtype of papillary thyroid carcinoma, vascular invasion is particularly important in the invasive encapsulated form, where it strongly predicts the risk of distant spread, especially to the lungs and bones. The pathology report often describes vascular invasion as:

Focal vascular invasion — Tumor cells are found in fewer than four blood vessels.
Extensive vascular invasion — Tumor cells are found in four or more blood vessels.

Extensive vascular invasion is associated with a higher risk of metastasis and may lead to more intensive treatment and closer follow-up.

Lymphatic invasion

Lymphatic invasion means that tumor cells are seen inside a lymphatic channel, a small thin-walled vessel that carries lymph from tissues toward the lymph nodes. The WHO 2022 classification asks pathologists to report lymphatic invasion separately from vascular invasion. Lymphatic invasion is less common in the invasive encapsulated form than in the infiltrative form, where it can serve as a route for tumor cells to reach nearby lymph nodes.

Surgical margins

A margin is the cut edge of the tissue removed at surgery. The pathologist examines the margins to determine whether the tumor was completely removed.

Negative margin — No tumor cells are seen at the cut edge. This is the most favorable result and is the strongest single predictor of long-term cure.
Positive margin — Tumor cells reach the cut edge. A positive margin indicates that some tumor may have been left behind in the neck. Additional treatment, such as further surgery or radioactive iodine therapy, may be considered.
Close margin — Tumor cells come within a few millimeters of the cut edge without reaching it. The pathology report may give the distance in millimeters.

Lymph nodes

Lymph nodes are small bean-shaped structures throughout the body, including the neck, that filter fluid and house immune cells. Cancer cells can travel from the thyroid to lymph nodes through lymphatic channels. The lymph nodes near the thyroid are grouped into anatomical regions called levels (numbered 1 through 7); the central neck (level 6) drains the thyroid most directly.

A neck dissection is sometimes performed when imaging or palpation suggests lymph node involvement. The pathology report will state how many lymph nodes were examined, how many contained tumor cells, the size of the largest tumor deposit in any node, and whether extranodal extension is present (meaning tumor cells have broken through the outer capsule of a lymph node into the surrounding tissue). Lymph node involvement is less common in the invasive encapsulated form of the follicular subtype than in the infiltrative form or in classic papillary thyroid carcinoma. When present, it is recorded as part of the pathologic stage and helps guide further treatment.

Biomarker and molecular testing

Biomarker testing is not required for every patient but can provide information about how the tumor is likely to behave and about treatment options if the cancer returns or has spread.

RAS mutations

The follicular subtype of papillary thyroid carcinoma most often carries mutations in one of the RAS family of genes (HRAS, KRAS, or NRAS). RAS-mutated tumors are more common in the invasive encapsulated form and tend to follow a more indolent (slow) course than tumors with BRAF mutations.

BRAF mutations

The BRAF V600E mutation is most common in the classic and infiltrative forms of papillary thyroid carcinoma. When present in the follicular subtype, it is more often found in the infiltrative form and may be associated with somewhat more aggressive behavior than seen in RAS-mutated tumors.

Other genetic findings

Less commonly, the follicular subtype of papillary thyroid carcinoma may show gene fusions involving NTRK, RET, ALK, or other genes. These findings are important because targeted drugs are available for some of these alterations and may be considered for tumors that have recurred or spread despite standard treatment. TERT promoter mutations, when present alongside BRAF or RAS, are associated with a higher risk of aggressive behavior.

For more information on biomarker testing in cancer, please visit our Biomarkers section.

Pathologic stage (pTNM)

Thyroid cancers are staged using the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th edition. The system has three parts: tumor (pT), nodal (pN), and metastasis (pM). For well-differentiated thyroid cancers, including the follicular subtype of papillary thyroid carcinoma, the stage grouping is unusual in that it also depends on the patient’s age at diagnosis (younger than 55 years vs 55 years and older), reflecting the substantially better prognosis seen in younger patients.

Tumor stage (pT)

pT1 — Tumor 2 centimeters or smaller, confined to the thyroid. pT1a is 1 centimeter or smaller; pT1b is greater than 1 centimeter and up to 2 centimeters.
pT2 — Tumor larger than 2 centimeters and up to 4 centimeters, confined to the thyroid.
pT3 — Tumor larger than 4 centimeters confined to the thyroid (pT3a), or tumor of any size with macroscopic extrathyroidal extension into nearby strap muscles only (pT3b).
pT4 — Tumor with extensive macroscopic extrathyroidal extension. pT4a invades into the upper airway, larynx, esophagus, or recurrent laryngeal nerve; pT4b invades into the spine, prevertebral fascia, or major blood vessels in the neck.

Nodal stage (pN)

pN0 — No tumor cells in any regional lymph nodes examined.
pN1a — Tumor cells in lymph nodes of the central neck (level 6) or upper mediastinum (level 7).
pN1b — Tumor cells in lymph nodes on the side of the neck (levels 2 to 5), behind the throat, or on the opposite side of the neck.

Stage grouping

For patients younger than 55 years at diagnosis, any tumor that has not spread to distant organs is Stage I, and any tumor that has spread to distant organs is Stage II. For patients 55 years and older, the stage groupings follow the more typical pattern based on the pT and pN categories. Your treatment team can explain the specific stage and what it means in your case.

What is the prognosis?

The overall prognosis for the follicular subtype of papillary thyroid carcinoma is very good. Most patients are treated successfully with surgery, with or without radioactive iodine, and live long lives. Five-year survival is over 95 percent for tumors confined to the thyroid, and even patients with more extensive disease often live many years.

Pathologic features that have been linked to a higher risk of recurrence or worse outcome include:

Larger tumor size — Especially tumors over 4 centimeters.
Macroscopic extrathyroidal extension — Tumor visibly invading structures outside the thyroid.
Extensive vascular invasion — Particularly important in the invasive encapsulated form.
Lymph node involvement — Especially when many nodes are involved or extranodal extension is present.
Distant metastasis at diagnosis — The strongest single predictor of poor outcome.
Positive surgical margin — Linked to higher risk of local recurrence.
BRAF mutation — When present, may be associated with somewhat more aggressive behavior in some patients.
TERT promoter mutation — Especially when combined with BRAF or RAS, associated with more aggressive disease.
Older age at diagnosis — Patients 55 years and older have somewhat worse outcomes than younger patients with otherwise similar tumors.

What happens after this diagnosis?

The pathology findings guide the next steps in care rather than dictating a single treatment. After complete staging, the treatment team typically considers:

Type of thyroid surgery — A lobectomy (removal of one lobe) is often sufficient for small, low-risk tumors. A total thyroidectomy (removal of the entire gland) is generally considered for larger tumors, tumors with extensive vascular invasion, extrathyroidal extension, lymph node involvement, or when radioactive iodine is planned.
Radioactive iodine (RAI) therapy — A treatment given by mouth as a capsule or liquid. The iodine is taken up by remaining thyroid cells, including any thyroid cancer cells, and the radiation destroys them. RAI is considered for tumors with high-risk features (extensive vascular invasion, macroscopic extrathyroidal extension, large lymph node involvement, distant spread) and is less often needed for small, low-risk tumors.
Thyroid hormone replacement — Required for life after a total thyroidectomy. The dose is often adjusted to keep thyroid-stimulating hormone (TSH) levels low, which can reduce the chance of recurrence.
Follow-up monitoring — Regular blood tests measure thyroglobulin (a protein made by thyroid cells, including thyroid cancer cells) and anti-thyroglobulin antibodies. A rising thyroglobulin level after treatment can be the first sign of recurrence. Neck ultrasound is also used to look for new disease in the thyroid bed or in the neck lymph nodes.
Treatment of recurrence or metastatic disease — Options can include further surgery, additional radioactive iodine, external beam radiation, or targeted therapy (such as drugs that target NTRK fusions, RET fusions, or BRAF V600E mutations). Choice of treatment depends on where the disease is, what genetic changes are present, and how the disease responds to initial treatment.
Genetic counseling — Considered when the patient is young, when multiple thyroid tumors are present, or when there is a family history of related cancers.
Multidisciplinary care — Endocrinology, endocrine surgery, nuclear medicine, medical oncology, radiation oncology, and (when relevant) genetics work together to plan treatment and follow-up.

Questions to ask your doctor

Which subtype do I have (invasive encapsulated or infiltrative), and how does this affect my treatment?
What was the size of my tumor, and was it confined to the thyroid?
Was capsular invasion or vascular invasion present, and how extensive was it?
Was extrathyroidal extension present (microscopic or macroscopic)?
Were the surgical margins clear?
How many lymph nodes were examined, and were any involved by tumor?
Was extranodal extension present?
What is my pathologic stage (pT, pN, and pM), and what does it mean given my age?
Did my tumor have a BRAF or RAS mutation, or a TERT promoter change?
Were any other gene changes identified that might affect treatment if the cancer returns?
Do I need radioactive iodine treatment, and why?
What dose of thyroid hormone replacement will I need, and how will the dose be monitored?
How often will I need follow-up blood tests, ultrasound, and other imaging?
What signs or symptoms should prompt me to seek urgent medical attention between follow-up visits?
Should I be referred for genetic counseling based on my findings or family history?